Literature DB >> 28991346

Surgical Outcome of Intermittent Exotropia With Improvement in Control Grade Subsequent to Part-time Preoperative Occlusion Therapy.

Seung Pil Bang, Dong Cheol Lee, Se Youp Lee.   

Abstract

PURPOSE: To evaluate the effect of improvement in the control grade of intermittent exotropia using part-time occlusion therapy on the final postoperative outcome.
METHODS: Control of intermittent exotropia was graded as good, fair, or poor in 89 consecutive patients with intermittent exotropia during their first visit. The patients were reevaluated after part-time preoperative occlusion therapy and divided into two groups (improvement and no improvement) according to whether they showed improvement in control grade. The surgical success rate was compared retrospectively between the two groups.
RESULTS: The mean angle of deviation on the first visit was 27.61 ± 5.40 prism diopters (PD) at distance and 29.82 ± 5.28 PD at near. There were significant improvements in the angles of deviation for distance (26.17 ± 5.09 PD) and near (27.26 ± 5.56 PD) after part-time occlusion (both P < .001). The 49 patients who had a significantly improved control grade had a significantly better surgical success rate (77.6%) than the 40 patients who did not (50%; P = .007).
CONCLUSIONS: Part-time occlusion therapy improves the control grade of intermittent exotropia, leading to a better likelihood of successful surgery and a reduction of the angles of deviation for distance and near. [J Pediatr Ophthalmol Strabismus. 2018;55(1):59-64.]. Copyright 2017, SLACK Incorporated.

Entities:  

Mesh:

Year:  2017        PMID: 28991346     DOI: 10.3928/01913913-20170703-05

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  1 in total

1.  Contrast Agent and Molecular Imaging Meta-Analysis of the Clinical Effect of Intelligent Image Sensor Combined with Visual Training in the Treatment of Children with Intermittent Exotropia in China.

Authors:  Haonan Sun; Shimiao Bai; Rujuan Liao; Aijun Han
Journal:  J Healthc Eng       Date:  2022-03-12       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.